CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 200 enrolled
Drug / intervention
TDF-FTC +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03826199
NCT03826199Phase 4Completed

Evaluation of Pre-exposure Prophylaxis Cascade in Pregnant and Breastfeeding Women in Cape Town, South Africa (Formative Study)

University of California, Los Angeles·interventional·Posted Feb 1, 2019·Updated Dec 1, 2023

In Brief

A Phase 4 clinical trial evaluating TDF-FTC and Counselling on PrEP in antenatal and postnatal care for Hiv. Completed, enrolled 200 participants across 1 site.

Detailed Summary

The overarching goal of this proposal is to evaluate the feasibility and acceptability of integrating PrEP into antenatal and postnatal care, to describe the cascade in women initiating PrEP in this setting, and to evaluate the reasons for attrition along the PrEP cascade in a cohort of pregnant and breastfeeding women. The specific aims are to: (1) Evaluate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services; (2) Describe the PrEP cascade of initiation, retention, and adherence in a cohort of 220 HIV-uninfected pregnant and breastfeeding women, (3) Evaluate attrition and associated factors across the PrEP cascade.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHiv
CountriesSouth Africa

Timeline

Phase 4CompletedFinished
20192020202120222023202420252026
First PostedFeb 1, 2019
Enrollment StartAug 23, 2019
Primary CompletionDec 1, 2021
Study CompletionSep 30, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 7.4 years ago

Interventions

TDF-FTCdrug

We will investigate the feasibility and acceptability of integrating PrEP into antenatal and postnatal/well-baby services. Upon enrollment in the cascade, all women will be offered PrEP counseling and information, and patients will be followed regardless of their choice to initiate PrEP or not. Participants who initiate PrEP will receive TDF-FTC during the study. At each study visit (every 3-months), women will receive counseling on PrEP adherence or on the risks and benefits of PrEP for women not yet initiated. We will evaluate PrEP initiation and adherence in pregnant and breastfeeding women (N=220) from first antenatal care visit through 12 months post-partum.

Counselling on PrEP in antenatal and postnatal carebehavioral

Information about PrEP will be integrated into regular group education in ANC by existing health care providers during discussion about HIV testing and treatment. During every study visit, PrEP counseling (including adherence counseling for women already on PrEP) will be provided. For women not on PrEP, counselling will be provided on PrEP and HIV prevention.